质子泵抑制剂在慢加急性肝衰竭治疗中的应用  

Application of proton pump inhibitors in acute-on-chronic liver failure

作　　者：姚俞昊 夏潇 张嘉鑫[2,4] 李小科 叶永安[2,4] YAO Yuhao;XIA Xiao;ZHANG Jiaxin;LI Xiaoke;YE Yong’an(The First Clinical Medical School,Beijing University of Chinese Medicine,Beijing 100029,China;Department of Gastroenterology,Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China;Department of Pneumology,Guang’anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;Liver Diseases Academy of Traditional Chinese Medicine,Beijing University of Chinese Medicine,Beijing 100700,China)

机构地区：[1]北京中医药大学第一临床医学院,北京100029 [2]北京中医药大学东直门医院消化科,北京100700 [3]中国中医科学院广安门医院呼吸科,北京100053 [4]北京中医药大学中医肝病研究院,北京100700

出　　处：《临床肝胆病杂志》2022年第12期2864-2867,共4页Journal of Clinical Hepatology

基　　金：国家自然科学基金(82174341);国家中医药管理局科研基金(JDZX2015300);北京中医药大学重点攻关项目(2022-JYB-ZDGG-115)。

摘　　要：质子泵抑制剂(PPI)是临床常用药物,目前在慢加急性肝衰竭人群中广泛应用。然而这一用药现状未得到美国胃肠病学会最新慢加急性肝衰竭临床指南推荐支持。笔者结合国内外指南或共识,综合最新研究进展,以评述PPI在慢加急性肝衰竭人群中的使用指征、可能获益及潜在风险,以期为临床慢加急性肝衰竭人群规范使用PPI提供参考。Proton pump inhibitors(PPIs) are commonly used in clinical practice and are currently widely used in people with acute-on-chronic liver failure(ACLF). However, such medication is still not supported by the recommendations in the latest version of Clinical guidelines for acute-on-chronic liver failure issued by American College of Gastroenterology. With reference to the guidelines or consensus statements in China and globally and the latest research advances, this article elaborates on the indications, possible benefits, and potential risks of PPIs used in people with ACLF, in order to provide a reference for the standardized use of PPIs in the population with ACLF in clinical practice.

关 键 词：肝功能衰竭 质子泵抑制剂 治疗应用 

分 类 号：R575.3[医药卫生—消化系统]